Immunome (NASDAQ:IMNM) Hits New 52-Week High – Here’s Why

Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high on Thursday . The stock traded as high as $25.55 and last traded at $25.7450, with a volume of 2059550 shares changing hands. The stock had previously closed at $24.87.

Analyst Ratings Changes

IMNM has been the topic of a number of recent research reports. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Immunome in a research note on Thursday, January 15th. Leerink Partners set a $40.00 target price on shares of Immunome in a research note on Monday, December 15th. Evercore ISI increased their target price on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Thursday. Finally, Truist Financial began coverage on shares of Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 price target for the company. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Immunome Stock Up 0.2%

The company’s fifty day moving average is $20.59 and its two-hundred day moving average is $14.92. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -8.77 and a beta of 2.22.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Sell-side analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall purchased 46,511 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was purchased at an average cost of $21.50 per share, with a total value of $999,986.50. Following the completion of the acquisition, the chief executive officer directly owned 853,247 shares of the company’s stock, valued at $18,344,810.50. This trade represents a 5.77% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Philip Tsai acquired 10,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were bought at an average cost of $20.49 per share, for a total transaction of $204,900.00. Following the acquisition, the insider owned 43,300 shares of the company’s stock, valued at $887,217. This represents a 30.03% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 68,518 shares of company stock valued at $1,453,958 over the last quarter. 7.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Assetmark Inc. purchased a new stake in Immunome in the third quarter valued at $39,000. BNP Paribas Financial Markets increased its position in shares of Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after purchasing an additional 3,802 shares during the last quarter. BIT Capital GmbH acquired a new stake in shares of Immunome in the 3rd quarter valued at about $69,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Immunome in the 3rd quarter valued at about $76,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.